Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function.

NCT01900548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-04-07

No results posted yet for this study

Summary

The aim of this study is to investigate potential metabolic effects of whey protein high in protein and high in leucine(HPHL) compared to soy protein high in protein and low in leucine(HPLL) in osteopenic patients in a randomized controlled intervention study.

The investigator hypothesize that HPHL will increase physical function and the ratio muscle mass / fat mass in this condition.

Conditions

  • Osteopenia

Interventions

DIETARY_SUPPLEMENT

Whey protein (HPHL)

The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.

DIETARY_SUPPLEMENT

Soy protein (HPLL)

The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.

DIETARY_SUPPLEMENT

Placebo (P)

Will not be given protein but the same energy content using maltodextrin (in a blended fashion).

OTHER

Resistance training

For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.

Sponsors & Collaborators

  • The Danish Council for Strategic Research

    collaborator OTHER
  • University of Aarhus

    lead OTHER

Principal Investigators

  • Bjørn Richelsen, Professor · The department of endocrinology, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900548 on ClinicalTrials.gov